Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study

Table 3

Multivariate analysis of prognostic factors for overall survival.

Variables	HR (95% CI)	value
BCLC class
C	1
B	0.462 (0.325, 0.657)	0.000
A	0.334 (0.222, 0.503)	0.000
AST (μmol/L)	1.000 (0.999, 1.001)	0.895
PLR	1.002 (1.000, 1.003)	0.015
NLR	1.007 (0.985, 1.030)	0.510
Tumor size	1.036 (1.000, 1.075)	0.053
TACE sessions	0.698 (0.642, 0.759)	0.000
Treatment method
D-TACE + liopodol	1
D-TACE	2.268 (1.361, 3.779)	0.002

Note. HR: hazard ratio; CI: confidence interval; BCLC: barcelona clinical liver cancer; AST: aspartate aminotransferase; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; D-TACE: drug-elutingbeads-transcatheter arterial chemoembolization.